FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) — Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 HighlightsTotal revenue for the fourth quarter was $62.1 million, an 8% increase compared to the fourth quarter of 2024, and the highest quarterly revenue achieved historically at CytekTotal revenue for the full year 2025 was $201.5 million, a 1% increase compared to the full year 2024Total recurring revenue, comprised of service and reagent revenues, grew 21% in 2025 compared to 2024, reaching 34% of total revenueAdjusted EBITDA in the year ended December 31, 2025 was $5.0 million, compared to $22.4 million for the full year 2024Expanded...

Initiates Non-GAAP 30% Rule of 40 Target By the Fourth Quarter of 2027 Approximated Subscription Revenue Contribution for ≥$30K ARR Customers Grew 22% in 2025 CHICAGO, Feb. 26, 2026 (GLOBE NEWSWIRE) — Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced financial results for its fourth quarter ended December 31, 2025. “Our team delivered strong results in the fourth quarter, highlighted by 15% total RPO growth and strong non-GAAP profitability,” said Ryan Barretto, CEO of Sprout Social. “We are announcing a new operating goal of reaching 30% on a non-GAAP basis against a Rule of 40 framework by fourth quarter 2027 as well as making continued investments to expand our reach deeper into the $30K+ customer segment, which...

Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following:Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX’s MSTAR technology platform with Regeneron’s proprietary binders to develop single molecule candidates that target multiple distinct biological pathways in several clinical indications. ModeX received an upfront payment and is entitled to potential milestone payments exceeding $200 million for each...

2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2025. “We closed out an outstanding year with a strong fourth quarter, reflecting the strength of our innovative test portfolio, disciplined execution and the dedication of the entire Castle team who continue to deliver meaningful impact for patients and clinicians every day,” said Derek Maetzold, president and chief executive officer of Castle Biosciences....

2025 marked the second full year of operation for all four vessels operated by Havila Kystruten AS (HKY) along the Norwegian coast. The year represents a clear step forward for the Company, reflecting improved operational stability, stronger commercial performance, and the effect of targeted investments made to support long term growth. In its second year of full operation, the fleet achieved exceptional operational uptime of 100% for the full year, up from 98% in 2024. These results are particularly strong given the operation of four new vessels and are a testament to the professionalism and dedication of the crew on board. The performance also reflects the benefits of a modern operating model, including an availability-based power by the hour arrangement with Kongsberg Maritime, which enables 24/7 monitoring and proactive technical management...

Paris (France), February 26, 2026 2025 annual resultsStrong performance driving significant cash generation and deleveragingSegment revenue of $1,165m, up +4% year-on-yearGeoscience revenue up +10% to $444m, driven by all our three core basins as well as the Middle East, and Earth Data revenue up +6% to $406m, fueled by market appetite for high-end data and sector consolidationStrong improvement in profitability, supported by operating efficiency gains across all business lines. Segment adjusted EBITDAs of $551m, up +21% year-on-year, representing a 47% margin vs 41% in 2024IFRS Net Income of $71m, up +40% compared with 2024Significant Net Cash Flow generation of $107m, exceeding the FY 2025 guidance of $100mContinued reduction in Net Debt (excluding IFRS 16) to $753mFY 2026 guidance: expected Net Cash Flow generation of...

2025 Normalised PBT of €10.6 Million Exceeds Outlook Sales for 2025: €484.3m, up 9% from 2024 Sales for Q4 2025: €136.7m up 6% from Q4 2024 Net Margin for 2025: €50.7 million, up €5.5 million EBITDA for 2025 was €22.8m up from €18.0m 2024 Normalised Profit Before Tax: €10.6 million vs. €7.4 million in 2024 Net Profit: €7.4 million, improved from a €2.8 million profit in 2024 EPS for 2025: Positive €0.2313 cents per share, vs. positive €0.0866 in 2024 Total Assets: €279.4 million, up €25.5 million from the beginning of the year Equity ratio at 29.5% compared to 30% at the end of 2024 2026 Normalised PBT Outlook: €11.5 million to €13.5 million The VA S-Europe division reported sales of €60.3 million in the fourth quarter, a 1.2% decrease compared to the same period in 2024. Total sales for the year amounted...

Hagnaður yfir afkomuspá ársins.  Hagnaður fyrir skatta af reglulegri starfsemi árið 2025 var 1,5 milljarður króna Rekstrartekjur samstæðunnar námu rúmlega 70,1 milljarði ISK (€484.3m) fyrir árið 2025 sem er 9% aukning frá 2024 Rekstrartekjur á fjórða ársfjórðungi 2025 námu 19,8 milljörðum ISK: (€136.7m), sem er aukning um 6% frá sama ársfjórðungi 2024 Framlegð 2025 var 7,3 milljarðar (€50.7m) hækkar um 799 milljónir ISK milli ára (€5.5m) EBITDA fyrir árið 2025 er 3,3 milljarðar ISK (€22.8m), en var 2,6 milljarður ISK (€18.0m) á árinu 2024 Hagnaður fyrir skatta af reglulegri starfsemi er 1,5 milljarður ISK (€10.6m) samanborinn við 1,1 milljarð ISK (€7.4m) 2024 sem er aukning um 457 milljónir ISK (€3.2m) Hagnaður ársins eftir skatta er 1,1 milljarður ISK (€7.4m) samanborinn við 402 milljóna ISK hagnað (€2.8m) 2024 Hagnaður...

Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis patients and the first idiopathic inflammatory myopathy patient treated with FT819; First systemic sclerosis patient reaching 3-month evaluation timepoint shows meaningful disease improvement using less-intensive conditioning chemotherapy FT819 Phase 1 enrollment expanded across 16 clinical sites in the U.S., U.K. and EU, with 15 systemic lupus erythematosus patients enrolled to date, supported by increased interest in FT819 safety, efficacy and on-demand accessibility profile Colorectal cancer patient shows greater than 50% reduction in CEA levels with tumor reduction across all target lesions after treatment with FT836, a MICA/B-targeted off-the-shelf...

Full Year Highlights – 2025 vs. 2024Verification and certification revenue: $20.1M vs. $20.6MProduct sales: $3.6M vs. $3.8MTotal revenue: $24.9M vs. $25.7MNet income: $1.5M vs. $2.1MDiluted EPS: $0.30 vs. $0.40Cash generated from operations: $1.6M vs. $2.7MCash & cash equivalents: $3.2M vs. $2.0M at 2024 year-endStock buybacks: 183,016 sharesTotal buybacks since plan inception (including private purchases): 1,374,652 shares at purchase price of approximately $15.2 millionFourth Quarter Highlights – 2025 vs. 2024Verification and certification revenue: $5.0M vs. $5.4MProduct sales: $0.7M vs. $0.9MTotal revenue: $6.0M vs. $6.7MNet loss of $0.2M vs. net income of $1.0MDiluted EPS: ($0.04) vs. $0.18Stock buybacks: 66,469 sharesCASTLE ROCK, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) — Where Food Comes...